Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(29%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_1
1
14%
Ph phase_2
3
43%
Ph phase_3
3
43%

Phase Distribution

1

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(4)
Completed(3)

Detailed Status

Completed3
Not yet recruiting2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 23 (42.9%)
Phase 33 (42.9%)

Trials by Status

not_yet_recruiting229%
recruiting229%
completed343%

Recent Activity

2 active trials
Showing 5 of 7
recruitingphase_3

A PAN-USR TB Multi-Center Trial

NCT06905522
recruitingphase_2

Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

NCT06114628
not_yet_recruitingphase_3

Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)

NCT07163143
not_yet_recruitingphase_3

Ultra-Short Regimen for Elderly DS-TB

NCT07076225
completedphase_1

PK Study of Anti-TB Drugs

NCT02457208
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06905522Phase 3

A PAN-USR TB Multi-Center Trial

Recruiting
NCT06114628Phase 2

Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

Recruiting
NCT07163143Phase 3

Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)

Not Yet Recruiting
NCT07076225Phase 3

Ultra-Short Regimen for Elderly DS-TB

Not Yet Recruiting
NCT02457208Phase 1

PK Study of Anti-TB Drugs

Completed
NCT01498419Phase 2

Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)

Completed
NCT01691534Phase 2

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7